19 . June , 2019 - Wednesday
Check todays hot topics or new products

Find a Drug: Advanced

Please Sign in or Register

All about: Abacavir Sulfate/Lamivudine/Zidovudine

Big Image Pronouncation: (ab-ah-KAV-ear SULL-fate/la-MIH-view-deen/zie-DOE-view-DEEN)
Class: Nucleoside analog reverse transcriptase inhibitor combination

Trade Names:
Trizivir
- Tablets abacavir sulfate 300 mg/lamivudine 150 mg/zidovudine 300 mg

Mechanism of Action

Pharmacology

Inhibits replication of HIV by incorporation into HIV DNA and producing incomplete, nonfunctional DNA.

Indications and Usage

Use alone and in combination with other antiretroviral agents for the treatment of HIV-1 infection.

Contraindications

Abacavir has been associated with fatal hypersensitivity reactions and should not be restarted following a hypersensitivity reaction to abacavir; hypersensitivity to any component of the product.

Dosage and Administration

Adults and Adolescents (at least 40 kg)

PO 1 tablet twice daily.

General Advice

  • May be used alone or in combination with other antiretrovirals.
  • Administer without regard to meals. Administer with food if GI upset occurs.
  • If a dose is missed, administer the missed dose as soon as noted and then administer the next dose at the regularly scheduled time.

Storage/Stability

Store tablets at controlled room temperature (59° to 86°F).

Drug Interactions

Atovaquone, fluconazole, methadone, probenecid, valproic acid

Zidovudine plasma concentrations may be elevated, increasing the pharmacologic and adverse reactions.

Doxorubicin, ribavirin, stavudine

Antagonistic relationship has been demonstrated between these agents and zidovudine.

Ethanol

Abacavir plasma concentrations may be elevated, increasing the pharmacologic and adverse reactions.

Ganciclovir, interferon-alpha, other bone marrow suppressive or cytotoxic agents

May increase the hematologic toxicity of zidovudine.

Methadone

Abacavir may increase methadone Cl, necessitating a dosage increase in some patients.

Nelfinavir, ritonavir

Zidovudine plasma concentrations may be reduced, decreasing the pharmacologic effects.

Trimethoprim/sulfamethoxazole

Serum concentrations of lamivudine may be elevated, increasing the pharmacologic and adverse reactions.

Zalcitabine

Lamivudine and zalcitabine may inhibit the intracellular phosphorylation of each other.

Laboratory Test Interactions

None well documented.

Adverse Reactions

Cardiovascular

Cardiomyopathy (postmarketing).

CNS

Headache (13%); fatigue, malaise (12%); depression (6%); anxiety (5%); dizziness, insomnia and other sleep disorders, paresthesia, peripheral neuropathy, seizures (postmarketing).

Dermatologic

Skin rash (5%); alopecia, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria (postmarketing).

EENT

Ear/nose/throat infections (5%).

Endocrine

Gynecomastia (postmarketing).

GI

Nausea (19%); nausea/vomiting (10%); diarrhea (7%); abdominal pain, anorexia, decreased appetite, dyspepsia, oral mucosal pigmentation (postmarketing).

Genitourinary

Stomatitis (postmarketing).

Hematologic-Lymphatic

Anemia, aplastic anemia, lymphadenopathy, splenomegaly, thrombocytopenia (postmarketing).

Hepatic

Elevated bilirubin, elevated transaminases, hepatic steatosis, lactic acidosis, pancreatitis, posttreatment exacerbation of hepatitis (postmarketing).

Lab Tests

Elevated CPK (7%); increased ALT (6%); neutropenia (5%); hyperamylasemia, hypertriglyceridemia (2%).

Metabolic

Body accumulation/fat redistribution (postmarketing).

Musculoskeletal

Musculoskeletal pain (5%); arthralgia, muscle weakness, myalgia, rhabdomyolysis (postmarketing).

Respiratory

Viral respiratory infections (5%); abnormal breath sounds/wheezing (postmarketing).

Miscellaneous

Hypersensitivity (8%); fever/chills (6%); anaphylaxis, vasculitis, weakness (postmarketing).

Precautions

Warnings

Intended only for patients whose regimen would otherwise include abacavir, lamivudine, and zidovudine.

Hypersensitivity reactions

Serious and sometimes fatal hypersensitivity reactions have been associated with abacavir. The reaction is a multi-organ clinical syndrome usually characterized by a sign or symptom in 2 or more of the following groups: fever; rash; GI, including abdominal pain, diarrhea, nausea, or vomiting; constitutional, including achiness, fatigue, or generalized malaise; and respiratory, including cough, dyspnea, or pharyngitis. Discontinue Trizivir as soon as a hypersensitivity reaction is suspected. Permanently discontinue Trizivir if hypersensitivity cannot be ruled out, even when other diagnoses are possible.

Following a hypersensitivity reaction to abacavir, never restart Trizivir or any other abacavir-containing product because more severe symptoms can occur within hours and may include life-threatening hypotension and death.

Reintroduction of Trizivir or any other abacavir-containing product, even in patients who have no identified history or unrecognized symptoms of hypersensitivity to abacavir therapy, can result in serious or fatal hypersensitivity reactions.

Hematologic toxicity

Zidovudine has been associated with hematologic toxicity, including neutropenia and severe anemia.

Lactic acidosis and severe hepatomegaly

Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with use of nucleoside analogues alone or in combination.

Exacerbations of hepatitis B

Severe acute exacerbations of hepatitis B have been reported in patients co-infected with hepatitis B virus (HBV) and HIV who have discontinued lamivudine. Closely monitor hepatic function with clinical and laboratory follow-up for at least several months in patients who discontinue Trizivir and are co-infected with HIV and HBV. Initiation of anti‐hepatitis B therapy may be warranted.


Monitor

Hematologic

Frequently monitor blood counts in patients with advanced HIV disease and in patients receiving combination therapy with Trizivir , interferon alpha, and ribavirin. Periodically monitor blood counts in HIV-infected patients with asymptomatic or early HIV disease.

Hepatic

Monitor patient with co-infection with HBV and HIV for posttreatment exacerbations of hepatitis B for several months after stopping treatment. Closely monitor patients receiving combination therapy with Trizivir , interferon alpha, and ribavirin; hepatic decompensation has been reported.

Hypersensitivity reaction

Monitor patient for signs/symptoms of allergic reaction to abacavir. Discontinue use and immediately notify health care provider if a sign or symptom in 2 or more of the following groups is noted: fever; rash; GI, including abdominal pain, diarrhea, nausea, or vomiting; constitutional, including achiness, fatigue, or generalized malaise; and respiratory, including cough, dyspnea, or pharyngitis. If hypersensitivity reaction is documented, ensure the reaction is reported to Abacavir Hypersensitivity Registry as noted in the package insert.

Lactic acidosis

Monitor patient for signs/symptoms of lactic acidosis (profound weakness or tiredness; unexpected stomach discomfort; feeling cold, dizzy, or light-headed; slow or irregular heartbeat). Withhold drug and notify health care provider immediately if suspected.


Pregnancy

Category C .

Lactation

HIV-infected mothers should not breast-feed their infants.

Abacavir

Undetermined.

Lamivudine and zidovudine

Excreted in breast milk.

Children

Not intended for use in children. Do not administer to adolescents who weigh less than 40 kg (88 lb) because it is a fixed-dose tablet that cannot be adjusted for this population.

Elderly

Use with caution, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and comorbidity.

Hypersensitivity

Fatal hypersensitivity reactions have been associated with abacavir use and have occurred within hours after reintroduction of abacavir in patients who have no identified history or unrecognized symptoms of hypersensitivity.

Renal Function

Because this is a fixed-dose combination, do not use for patients requiring dose adjustments (eg, Ccr less than 50 mL/min).

Hepatic Function

Contraindicated in patients with impaired hepatic function because this is a fixed-dose combination that cannot be adjusted for hepatically-impaired patients.

Bone marrow suppression

Use with caution in patients who have bone marrow compromise evidenced by granulocyte count less than 1,000 cells/mm 3 or Hgb less than 9.5 g/dL.

Fat redistribution

Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, breast enlargement, and cushingoid appearance have been reported. Mechanism and long-term consequences of these events is unknown.

Fixed-dose combination

Contains abacavir, lamivudine, and zidovudine in a fixed-dose tablet. Ensure patient is not receiving abacavir, lamivudine, or zidovudine in any other dose forms. Because the dose cannot be adjusted, do not administer to patients who weigh less than 40 kg or other patients who may require a dose adjustment (eg, dose-related toxicity, hepatic or renal impairment).

Immune reconstitution syndrome

Has been reported in patients treated with combination antiretroviral therapy.

Myopathy

Myopathy and myositis, with pathological changes similar to that produced by HIV disease, have been associated with prolonged use of zidovudine.

Overdosage

Symptoms

Confusion, dizziness, drowsiness, headache, lethargy, nausea, vomiting.

Patient Information

  • Caution patient not to take any other HIV medications that contain abacavir, lamivudine, or zidovudine.
  • Advise patient to review Medication Guide before starting therapy and to read and check for new information each time the medication is refilled.
  • Advise patient to review, and carry with them at all times, the Warning Card summarizing the symptoms of abacavir hypersensitivity reaction.
  • Advise patient that this drug may be used alone or in combination with other HIV medications. Instruct patient taking other HIV medications to continue to take them as prescribed by health care provider.
  • Instruct patient to take exactly as prescribed and not to change the dose or discontinue therapy unless advised by health care provider.
  • Instruct patient to take 1 tablet twice daily without regard to meals but to take with food if stomach upset occurs.
  • Instruct patient that if a dose is missed to take as soon as remembered and then take the next dose at the usual scheduled time.
  • Instruct patient to discontinue use and notify health care provider immediately if 2 or more of the following symptoms occur: fever; rash; diarrhea, nausea, stomach area pain, or vomiting; achiness, extreme tiredness, or generalized body discomfort; cough, shortness of breath, or sore throat.
  • Caution patient not to restart this medication or any other abacavir-containing medication if they experience a hypersensitivity reaction to this medication. Explain to patient that restarting abacavir or an abacavir-containing product could cause a more serious, and possibly fatal, reaction.
  • Caution patient that if therapy is interrupted for a few days for reasons other than a hypersensitivity reaction (eg, interruption in drug supply) and is then restarted, there is a risk of experiencing a serious or fatal hypersensitivity reaction. Advise patient to talk with health care provider before restarting the medication on their own. Advise patient that if health care provider tells them they can take the medication again, to start taking it when they are around medical help or people who could call a health care provider if necessary.
  • Caution patient that medication can cause a rare but serious condition called lactic acidosis with liver enlargement and that profound weakness or tiredness; unexpected stomach discomfort; feeling cold, dizzy, or light-headed; or slow or irregular heartbeat may be symptoms of this condition. Instruct patient to immediately inform health care provider if these symptoms develop.
  • Caution patient who has concurrent infection with HBV that their hepatitis may worsen if therapy is stopped and that their liver function should be followed closely for several months after stopping the medication. Advise patient that they may need to begin taking anti-HBV medications.
  • Advise patient that medication may cause changes in body fat distribution (eg, increased amount of fat in upper back and neck, breasts, and around the back, chest, and stomach area; loss of fat from arms, legs, and face) and that the cause and long-term health effects of these changes is not known at this time. Advise patient to report changes in body fat distribution to health care provider.
  • Advise patient that long-term use can cause muscle weakness and to report this to health care provider immediately if noted or suspected.
  • Inform patient that drug does not completely eliminate HIV virus and does not reduce the risk of transmitting HIV to others through sexual contact or blood contamination. Instruct patient that appropriate precautions must still be followed.
  • Advise patient that drug is not a cure for HIV infection and that they may continue to acquire illnesses associated with HIV infection, including opportunistic infections, and that they should remain under a health care provider's care.
  • Instruct mother not to breast-feed her infant because of the risk of transmitting the HIV virus to the infant, and the potential for serious adverse reactions from medication transmitted to her infant through breast milk.

Recent Drug Updates at DrugIndexOnline:





Acilac Acilac
Some commonly used brand names are: In the U.S.— Agoral 35 Alophen 25 Alphamul 30 Alramucil Orange 7 Alramucil Regular 7 Bisac-Evac 25 Black-Draught 26 Black-Draught Lax-Senna 32 Carter's Little Pills 25 Cholac 14 Citroma 16 Citrucel Orange Flavor 3 Citrucel Sugar-Free Orange Flavor 3 Col more...

Feverfew Feverfew
Generic Name: Feverfew (Tanacetum parthenium) (Not applicable.) Brand Name: Generics only. No brands available.Feverfew is used for:Migraine headaches, arthritis, menstrual pain, and to reduce fever. It may also have other uses. Check with your pharmacist for more details regarding the particula more...

Interferon Alfa-2b Solution Interferon Alfa-2b Solution
Generic Name: Interferon Alfa-2b Injection Solution (in-ter-FEER-on AL-fuh) Brand Name: Intron-AInterferon Alfa-2b Solution can cause or worsen some serious medical conditions, including psychiatric conditions (eg, depression), immune system problems (autoimmune conditions such as lupus or rheum more...

Iron Dextran Iron Dextran
Some commonly used brand names are: In the U.S.— DexFerrum 4 Femiron 1 Feosol Caplets 3 Feosol Tablets 3 Feostat 1 Feostat Drops 1 Feratab 3 Fer-gen-sol 3 Fergon 2 Fer-In-Sol Drops 3 Fer-In-Sol Syrup 3 Fer-Iron Drops 3 Fero-Gradumet 3 Ferospace 3 Ferralet 2 Ferralet Slow Release 2 Ferraly more...

Myobloc Parenteral-Local Myobloc Parenteral-Local
Some commonly used brand names are: In the U.S.— Myobloc Category Neuromuscular blocking agent Description Botulinum toxin type B (BOT-yoo-lye-num ) is used to treat abnormal head position and neck pain that is a result of cervical dystonia. Botulinum toxin type B is injected int more...

Nizatidine Nizatidine
Pronouncation: (nye-ZA-ti-deen) Class: Histamine H 2 antagonist Trade Names: Axid - Solution, oral 15 mg/mL Trade Names: Axid AR - Tablets 75 mg Trade Names: Axid Pulvules - Capsules 150 mg - Capsules 300 mg Apo-Nizatidine (Canada) Novo-Nizatidine (Canada) PMS-Nizatidine (Canada) Mechanism of Actio more...

OxyContin OxyContin
Generic name: Oxycodone hydrochloride Brand names: OxyContin Why is OxyContin prescribed? OxyContin is a controlled-release form of the narcotic painkiller oxycodone. It is prescribed for moderate to severe pain when continuous, around-the-clock relief is needed for an extended period of time. more...

Permax Permax
Generic Name: pergolide Dosage Form: Tablets usp Warning Cardiac Valvulopathy and Fibrotic Complications Cardiac Valvulopathy The use of pergolide has been shown to increase the risk of cardiac valvular disease involving one or more valves. Some patients have required valve replacement, and dea more...